The report showed an approximately 25 percent reduction in 10 of the 12 symptoms studied, including the common complaints of lingering fatigue and brain fog.
the findings in an online post that emphasizes the urgency of developing treatments for what is now widely recognized as a mass-disabling condition.“We have no treatment that has been validated to treat Long Covid,” Topol wrote. “Rigorous, randomized, definitive clinical trials are long overdue.”
“We could do a long-term follow up to determine if both groups have the same or different rates of persistent symptoms,” said David Putrino, director of rehabilitation innovation at Mount Sinai Health System in New York.Pfizer said the company is “working with multiple institutions toward the start of studies to evaluate Paxlovid for potential use in addressing long covid.” In its 2022 financial guidance, the company reported Paxlovid revenue of $22 billion.
There is no data to show whether those previously healthy young people would reap the same benefits as people at risk of severe disease. Putrino cautioned that the study’s promising results may be related to the antiviral’s ability to reduce the severity of acute illness that can lead to lingering complications such as lung fibrosis from pneumonia, pericarditis from inflammation and what’s known as post-ICU syndrome, rather than the other symptoms he commonly sees.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Paxlovid reduces risk of long Covid, Veterans Affairs study finds | CNNPaxlovid, the antiviral pill that reduces the risk of hospitalization and death from Covid-19, also reduces the risk of long Covid, according to a new study by researchers at the US Department of Veterans Affairs.
Consulte Mais informação »
Paxlovid reduces long-COVID risk, VA study findsPfizer's antiviral pill Paxlovid can reduce the risk of long COVID symptoms like organ damage, per a pre-print study released by the Dept. of Veterans Affairs.
Consulte Mais informação »
Paxlovid Cuts the Risk of Long COVID: VA StudyPaxlovid, the antiviral drug designed to reduce the risk of death and hospitalization from COVID-19, may also help cut the chances a person will develop long COVID, a study by the U.S. Department of Veterans Affairs shows.
Consulte Mais informação »
Paxlovid Cuts the Risk of Long COVID: VA StudyPaxlovid, the antiviral drug designed to reduce the risk of death and hospitalization from COVID-19, may also help cut the chances a person will develop long COVID, a study by the U.S. Department of Veterans Affairs shows.
Consulte Mais informação »
New VA study finds Paxlovid may cut the risk of long COVIDFor those at high risk, Pfizer's antiviral drug helps stave off severe COVID-19. Now research suggests it may also reduce their chances of long COVID.
Consulte Mais informação »